Inhibitory Effect of Naringenin on MMP-9 Activity and Expression in HT-1080 Cells

Naringenin이 NF-$\kappa$B, AP-1 억제를 통한 MMP-9 활성 및 발현 억제 효과

  • Chae, Soo-Chul (Department of Biology, Chonnam National University) ;
  • Kho, Eun-Gyeong (Department of Biology, Chonnam National University) ;
  • Seo, Eun-Sun (Department of Biology, Chonnam National University) ;
  • Ryu, Geun-Chang (Department of Ophthalmic Optics, Dongshin University) ;
  • Na, Myung-Suk (Department of Beauty & Science, Kwangju Women's University) ;
  • Kim, In-Suk (Department of Ophthalmic Optics of Chodang University) ;
  • Lee, Jong-Bin (Department of Biology, Chonnam National University)
  • Published : 2009.02.28

Abstract

The chemopreventive effects of naringenin derived from citrus on tumor migration and the possible mechanisms involved in this protection were investigated in HT-1080 tumor cells. In this study, we found that naringenin reduced phorbol 12-myristate 13-acetate (PMA)-enhanced matrix metalloproteinases (MMP)-9 activation in a dose-dependant manner and further inhibited HT-1080 cell migration. In addition, naringenin suppressed PMA-enhanced expression of MMP-9 protein, mRNA and transcription activity levels through suppression of nuclear factor $\kappa$B (NF-$\kappa$B) activation and activator protein-1 (AP-1) translocation without changing tissue inhibitor of metalloproteinase (TIMP)-1 level. Therefore, our results suggested that the inhibitory effects of naringenin on MMP-9 activation, relation of tumor migration in vitro possibly involve mechanisms related to its ability to suppress PMA-enhanced MMP-9 gene and protein expression through NF-$\kappa$B activation and AP-1 translocation. Overall, naringenin may be a valuable anti-invasive drug candidate for cancer therapy.

Naringenin은 flavonoid구조의 감귤류 과피에 다량 함유되어 있으며 항암 및 항산화 등의 다양한 생리활성을 가지는 것으로 보고되었다. 이에 본 연구에서는 HT-1080 섬유육종세포의 전이에 대한 영향을 조사하였다. 먼저 Naringenin이 암세포의 이동에 미치는 영향을 알아보기 위해 migrationassay를 한 결과, Naringenin이 암세포의 이동을 농도 의존적으로 억제시켰다. 암의 전이에 있어서 매우 중요한 역할을 하는 단백질분해효소인 matrix metalloproteinase-9 (MMP-9)의 활성도를 측정하기 위해 gelatin zymography를 한 결과, Naringenin이 PMA에 의해 증가된 MMP-9의 효소 활성도를 농도 의존적으로 감소시켰다. 또한 MMP-9와 TIMP-1의 유전자 발현에 대한 Naringenin의 영향을 RT-PCR방법으로 조사한 결과, Naringenin이 PMA에 의해 증가된 MMP-9의 mRNA발현을 농도 의존적으로 감소시켰으나 TIMP-1의 mRNA발현에는 변화가 없었다. MMP-9발현 감소에 관여하는 전사조절인자를 확인하기 위해 promoterassay를 한 결과, Naringenin이 PMA에 의해 증가된 MMP-9 및 NF-$\kappa$B, AP-1의 Promoter활성을 농도 의존적으로 감소시 켰다. 또한 MMP-9의 전자조절인자인 NF-$\kappa$B와 AP-1의 결합 활성도를 electrophoretic mobility shift assay로 확인한 결과 Naringenin이 PMA에 의해 증가된 NF-$\kappa$B와 AP-1의 결합 활성도를 농도 의존적으로 감소시켰다. 결론적으로 Naringenin이 전사조절인자인 NF-$\kappa$B와 AP-1의 활성을 억제함으로써 MMP-9의 유전자 발현 및 효소 활성을 억제하고 그 결과 암세포의 이동과 침윤을 억제하는 것을 알 수 있다.

Keywords

References

  1. Ameer B, RA Weintraub, JV Johnson, RA Yost and RL Rou-seff. 1996. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin. Pharmacol. Ther. 60:34-40 https://doi.org/10.1016/S0009-9236(96)90164-2
  2. Cassady JM, WM Baird and CJ Chang. 1990. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J. Nat. Prod. 53:23-41 https://doi.org/10.1021/np50067a003
  3. Chambers AF and LM Matrisian. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1260-1270 https://doi.org/10.1093/jnci/89.17.1260
  4. De Clerck Y A, MI Darville, Y Eeckhout and GG Rousseau. 1994. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 139:185-191 https://doi.org/10.1016/0378-1119(94)90753-6
  5. Dupuy J, JF Larrieu, A Sutra and M Alvinerie. 2003. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Vet. Parasitol. 112:337-347 https://doi.org/10.1016/S0304-4017(03)00008-6
  6. Fujiki H. 2005. Green tea: Health benefits as cancer preventive for humans. Chem. Rec. 5:119-132 https://doi.org/10.1002/tcr.20039
  7. Garg A and BB Aggarwal. 2002. Nuclear transcription factor $\kappa$B as a target for cancer drug development. Leukemia 16:1053-1068 https://doi.org/10.1038/sj.leu.2402482
  8. Ghosh S and M Karin. 2002. Missing piecesin the NF-$\kappa$B puzzle. Cell 109:81-96 https://doi.org/10.1016/S0092-8674(02)00703-1
  9. Hodek P, P TrefiI and M Stiborova. 2002. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139:1-21 https://doi.org/10.1016/S0009-2797(01)00285-X
  10. Jang IM, JH Kim and DS Han. 1982. Toxicological evaluation of medicinal plants used for herbal drugs (lV). Acute toxicity and antitumor activity. Kor. J. Pharmacogn. 13:62-69
  11. John A and G Tuszynski. 2001. The role of mmatrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res. 7: 14-23 https://doi.org/10.1007/BF03032599
  12. Kanno SI, A Tomizawa. T Hiura, Y Osanai, A Shouji, M Ujibe, T Ohtake, K Kimura and M lshikawa. 2005. lnhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol. Pharm. Bull. 28:527-530 https://doi.org/10.1248/bpb.28.527
  13. Kwon OS. BY Kim, KA Kim, MS Kim, HC Oh. BS Kim. YH Kim and JS Ahn. 2004. Effect of the hesperetin and naringenin on $pp60^{v-src}$-induced NF-$\kappa$B activation. Kor. J. Pharmacogn. 35:244-249
  14. Liabakk NB, I Talbot, RA Smith, K Wikinson and F Balkwill. 1996. Matrix metalloproteinase 2 (MMP-2) and metalloproteinases 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 56:190-196
  15. Moynagh PN. 2005. NF-$\kappa$B pathway. Cell Sci. 118:4582-4659
  16. So FV, A Guthrie, AF Chambers and KK Carroll. 1997. Inhibition of proliferation of estrogen receptor-positive MCF-7 human. Cancer Lett. 112:127-133 https://doi.org/10.1016/S0304-3835(96)04557-0
  17. Van Acker F A, O Schouten, GR Haenen, WJ Van der Vijgh and A Bast. 2000. Flavonoids can replace a-tocopherol as an antioxidant. FEBS. Lett. 473:145-148 https://doi.org/10.1016/S0014-5793(00)01517-9